For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Harpoon Therapeutics, Inc.

Calculating rank

USPTO Granted Patents = 25

% Expired Patents = 12.0

EPO Patents = 4

Trademarks = 2

Forward Citations = 174

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Richard J Austin (21 out of 25 patents)

Holger Wesche (19 out of 27 patents)

Bryan D Lemon (17 out of 25 patents)

4. Robert B Dubridge (11 out of 49 patents)

5. Jeanmarie Guenot (11 out of 17 patents)

6. Luke Evnin (9 out of 24 patents)

7. Patrick A Baeuerle (6 out of 35 patents)

8. Pui Seto (5 out of 5 patents)

9. Vanitha Ramakrishnan (3 out of 20 patents)

10. Shuoyen Jack Lin (2 out of 2 patents)

11. Kathryn Kwant (2 out of 3 patents)

12. Sony S Rocha (2 out of 2 patents)

13. Kevin Wright (1 out of 1 patent)

14. Kevin Wright (0 patent)

Core Competencies:

Binding Proteins

Trispecific Proteins

EGFR Binding

B Cell Maturation Antigen

DLL3 Binding

Single Domain Proteins

Prostate Specific Membrane Antigen

Antigen Targeting

25 patents: Sort by Forward Citations

1. 12528859 - SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN (2026-01-20),

2. 12516128 - EPCAM BINDING PROTEINS AND METHODS OF USE (2026-01-06),

3. 12415860 - Binding moiety for conditional activation of immunoglobulin molecules (2025-09-16),

4. 12371504 - Trispecific proteins and methods of use (2025-07-29),

5. 12195544 - EGFR binding proteins and methods of use (2025-01-14),

6. 12084518 - Trispecific binding proteins and methods of use (2024-09-10),

7. 11976125 - B cell maturation antigen binding proteins (2024-05-07),

8. 11807692 - DLL3 binding proteins and methods of use (2023-11-07),

9. 11623958 - Single chain variable fragment CD3 binding proteins (2023-04-11),

10. 11607453 - Mesothelin binding proteins (2023-03-21),

11. 11535668 - Inducible monovalent antigen binding protein (2022-12-27),

12. 11453716 - Single domain serum albumin binding protein (2022-09-27),

13. 11180563 - FLT3 binding proteins and methods of use (2021-11-23),

14. 11136403 - Trispecific proteins and methods of use (2021-10-05),

15. 10954311 - Trispecific binding proteins and methods of use (2021-03-23),

Company Overview

Harpoon Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative therapies for cancer and other serious diseases. The company focuses on its proprietary TriTAC-XR platform, which enables the creation of targeted therapeutics designed to engage the immune system more effectively. By leveraging advanced protein engineering and drug design, Harpoon aims to enhance treatment options and improve patient outcomes in oncology and beyond.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

25 Patents

#54 in South San Francisco, CA

#3,162 in California

#13,379 in US

#25,748 in the World

South San Francisco, CA, United States of America

Harpoon Therapeutics, Inc.

Forward Citations = 174

13 inventors:

Richard J Austin (21 out of 25 patents)

Holger Wesche (19 out of 27 patents)

Bryan D Lemon (17 out of 25 patents)

4. Robert B Dubridge (11 out of 49 patents)

5. Jeanmarie Guenot (11 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Harpoon Therapeutics, Inc.. Retrieved from https://idiyas.com/company/harpoon-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…